ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Diphenhydramine

Also written as “Ibuprofen and Diphenhydramine Citrate”, “Diphenydramine” and “Diphenhydramine Hydrochloride Injection”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Nasal Obstruction · Multiple Sclerosis · Depressive Disorder, Major · Urticaria, led by 9 companies.

Drug pageDiphenhydramine: every studyMany companies study it; this page follows only the 13 they lead. All 67 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 20, 200813 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson40 open or runningphase 4since Mar 20, 2008Mar 20, 2008none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jan 20, 2010Jan 20, 2010none ahead
Lumara Healthits history only10 open or runningphase 2since Dec 26, 2007Dec 26, 2007none ahead
Lunan Pharmaceutical Groupits history only11 open or runningphase 3since Feb 6, 2025Feb 6, 2025none ahead
Otsukaits history only10 open or runningphase 1since Nov 25, 2012Nov 25, 2012none ahead
Overseas Pharmaceuticalsits history only10 open or runningphase 1since Feb 6, 2023Feb 6, 2023none ahead
Pfizerits history only10 open or runningphase 1since May 5, 2010May 5, 2010none ahead
Procter and Gambleits history only10 open or runningphase 4since Oct 14, 2015Oct 14, 2015none ahead
TerSera Therapeuticsits history only10 open or runningphase 2since Dec 3, 2019Dec 3, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2008First study: phase 1 study in Nasal ObstructionFirst studyNCT00662337 · 36 enrolled
  2. Mar 20, 2008Phase 4 study in Nasal ObstructionNCT00648973 · 1,021 enrolled · United States
  3. Sep 26, 2008Phase 1 study in Rhinitis, AllergicNCT00762749 · 36 enrolled · United States
  4. May 29, 2015Phase 1 study in Depressive Disorder, MajorNCT02476058 · 48 enrolled · Belgium, Germany, Netherlands

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor antagonist; Histamine H1 receptor antagonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
desloratadineruleOrganonphase 440
fexofenadineruleSanofiphase 438
bilastinerulefaes-farma-s-aphase 419

Studies

All 4 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02476058Depressive Disorder, Major · Belgium, Germany, Netherlands1CompletedJan 4, 201648
NCT00762749Rhinitis, Allergic · United States1CompletedNov 200836
NCT00662337Nasal Obstruction1CompletedNov 200636
NCT00648973Nasal Obstruction · United States4CompletedMay 20071,021

How it is read

Names in the registry

  • “Diphenhydramine”, 2 entries
  • “Ibuprofen and Diphenhydramine Citrate”, 2 entries
  • “Diphenydramine”, 1 entry
  • “Diphenhydramine Hydrochloride Injection”, 1 entry
  • “Diphenhydramine 50 mg/mL”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.